ACTRN12605000538640
Recruiting
未知
Radiation sensitivity in prostate cancer patients
ROYAL ADELAIDE HOSPITA0 sites100 target enrollmentSeptember 28, 2005
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- ROYAL ADELAIDE HOSPITA
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The first stage of the project is a case\-control study involving 100 untreated Prostate cancer cases and 100 controls. Cases and controls will be matched for age, gender, familial history of cancer and smoking status.The second stage of the project is a prospective study aimed at determining whether the selected biomarkers predict abnormal tissue reaction in 100 localized Prostate cancer patients treated with RT who have ECOG 0\-2 performance status and do not have a constant requirement for aperients or anti\-diarrhoeal medication. Age, weight, tumour grade, family history of prostate cancer, use of anti\-male hormone therapy and smoking status will be recorded.
Exclusion Criteria
- •No exclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The effect of radiation therapy of the prostate on parameters, which can be acquired by magnetic resonance tomography: relaxation times, apparent diffusion coefficient and perfusion.C61Malignant neoplasm of prostateDRKS00002954niversitätsklinikum Freiburg6
Completed
Not Applicable
Radiotherapy for prostate cancer: Influence of fiducial marker on diffusion weighted MR imageJPRN-UMIN000036326Asahi University20
Recruiting
Not Applicable
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation TherapyProstatic NeoplasmsProstate CancerNCT01834001National Cancer Institute (NCI)300
Active, not recruiting
Not Applicable
Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate CancerProstate CancerNCT01617161Massachusetts General Hospital454
Completed
Not Applicable
Patient involvement in prostate cancer treatment decisionsProstate cancerCancerISRCTN97145188Dutch Cancer Society (The Netherlands)300